RECOVERY & TISSUE REPAIR / FAQ
Questions From the Literature
Direct, citation-anchored answers to the questions readers bring most often to BPC-157 and TB-500.
What does BPC-157 do in the body?
In animal models, BPC-157 is described as a cytoprotective and regenerative peptide. Its repair effects are most consistently tied to angiogenesis — encouraging new blood vessels to grow into injured tissue by up-regulating VEGFR2, the vessel-growth signal receptor [4]. It has accelerated healing in rat models of gastric ulcers [5] and tissue repair more broadly. Crucially, almost all of this is preclinical; human evidence is limited to three small pilot studies [2].
Is BPC-157 a growth hormone?
No. BPC-157 is not a growth hormone and does not act as one. It is a synthetic fifteen-amino-acid peptide derived from a protein in gastric juice. One related point sometimes causes confusion: in tendon cells, BPC-157 has been reported to sensitize the growth-hormone receptor, which may amplify the body's own growth-hormone signaling [2]. Making a receptor more responsive is not the same as being a growth hormone. BPC-157 does not replace or substitute for growth hormone.
Does BPC-157 work immediately?
The peptide clears from the bloodstream rapidly. PK work in rats and dogs found an elimination half-life under 30 minutes, with rapid breakdown into fragments that re-enter normal amino-acid metabolism [3]. Whether any repair effect appears quickly is a separate question: published healing data from animal studies are measured over days to weeks, not as immediate outcomes. This digest does not advise on use or timing.
Does BPC-157 damage the liver?
Available data do not show liver harm, but the dataset is very thin. In the 2025 first-in-human intravenous safety pilot, BPC-157 up to 20 mg in two healthy adults produced no measurable changes in hepatic, cardiac, renal, thyroid or glucose biomarkers [1]. That is reassuring as far as two people goes. The 2025 narrative review notes that without long-term, large-sample human data the overall safety profile remains genuinely unknown [2]. Nothing here is medical advice.
What is TB-500, and what does the "TB" stand for?
"TB" refers to thymosin beta — specifically thymosin beta-4 (Tβ4), the natural protein TB-500 derives from. TB-500 itself is a synthetic seven-amino-acid fragment, Ac-LKKTETQ, corresponding to the actin-binding region (residues 17-23) of that protein [10]. An important nuance: in commerce and anti-doping labs, "TB-500" means the short fragment, but most published efficacy research uses the full-length Tβ4 protein, which is roughly five times larger [8]. The name points at a fragment while much of the reputation rests on the whole protein.
What is TB-500 used for in research?
In research, TB-500 (and, more often, full-length thymosin beta-4) is studied for tissue repair driven by actin regulation: cell migration, angiogenesis, reduced scarring, and anti-inflammatory signaling, across dermal wound, corneal, cardiac and CNS models [8]. A human Phase 1 study of full-length Tβ4 in 40 volunteers assessed safety and pharmacokinetics [9]; a rat stroke study examined neurological recovery [7]. There are no completed controlled clinical trials of the TB-500 fragment itself for any indication [8].
Does TB-500 work for muscle tears and recovery from exercise?
There is no controlled human evidence that the TB-500 fragment helps muscle tears or exercise recovery. The mechanistic rationale comes from thymosin beta-4's role in actin regulation and cell migration [8], but a 2026 Sports Medicine review concluded that favorable animal outcomes for unapproved musculoskeletal peptides including TB-500 have not been matched by rigorous human safety or efficacy data [6]. In a muscular-dystrophy mouse model, chronic Tβ4 increased regenerating fibers but did not improve muscle strength [8]. TB-500 is also prohibited in sport [6].
How are BPC-157 and TB-500 different?
Size, origin and mechanism all differ. BPC-157 is fifteen amino acids from gastric juice; its primary documented mechanism is VEGFR2-mediated angiogenesis [4]. TB-500 is seven amino acids from the actin-binding region of thymosin beta-4; its mechanism is G-actin sequestration enabling cell migration and wound-closure [10]. BPC-157 has more animal studies and three small human pilots; TB-500's human data come from the full parent protein, not the fragment [2][8]. Neither is approved; both are WADA-prohibited.
Are these peptides legal to purchase?
Legal status varies by jurisdiction. In most countries these are sold as research chemicals for laboratory use only — not as medicines, not for human consumption. They are not approved drugs anywhere. Both are prohibited in sport by WADA [2][6]. In some jurisdictions (for example Australia and New Zealand) TB-500 / thymosin beta-4 is a controlled prescription substance [6]. BPC-157 has been placed by the FDA in a category under review for compounding eligibility. Readers should verify the regulations in their own jurisdiction.
Is there any human evidence for either peptide?
Very limited. For BPC-157: a 2025 intravenous safety pilot in two healthy adults found no adverse events [1]; a separate 2025 narrative review counts only three small human pilot studies total and no large controlled trials [2]. For TB-500 (as its parent, full-length thymosin beta-4): a randomized placebo-controlled Phase 1 IV study in 40 healthy volunteers found it well tolerated [9]. No controlled clinical trials of the TB-500 fragment itself exist in humans. Neither compound has reached Phase 3 trials [6][8].
What are the key safety concerns?
For BPC-157: the main concerns are an overwhelmingly preclinical evidence base from a single research group, unregulated supply (purity and identity unverified outside formal studies), and WADA prohibition [2]. For TB-500: the identity gap between the marketed fragment and the studied full protein, a theoretical pro-migratory tumor signal from Tβ4's known role in cancer biology, non-monotonic dosing responses in animal work, and WADA prohibition [6][8]. For both: no long-term human safety data exist.